The evolving regulatory landscape and the impact of Brexit
The University of Oxford is host of a very vibrant research and innovation ecosystem. In the recent year, the Oxford Institute of Biomedical Engineering, through its spin-out Organox, has seen its first therapeutic device, a novel organ preservation device, approved by the FDA in 2021. The device is the results of more than 15 years of cross-disciplinary works between several department at the University and its spin-out. OxVent, a social enterprise from the University of Oxford and King’s College London rapidly developed a deployable and low-cost ventilator due to the accrued needs through the Covid-19 pandemic in a record time. Developing a medical device is however no walk-in the park and require a broad set of knowledge, collaborative work, between scientific, commercial, legal and regulatory teams.
In this webinar series, we intend to bring knowledge, tools and a network to academic researchers developing their own device and ideas at the university. This series aims to support the academic community transitioning from basic and fundamental research into the translational research space, where the bases for a commercial, or non-for profit and impact driven projects, needs to be lay down. Following the 2021 webinar series ‘Developing a Medical Device: turning your idea into a successful commercial product that’s improving detection, diagnosis or treatment’, we will continue the series in 2022 to address topics.
In this session we explore the evolving regulatory landscape and the impact of Brexit. This session will be led by The British Standard Institute.
6 July 2022, 11:00 (Wednesday, 11th week, Trinity 2022)
Webinar - tickets via Eventbrite
The British Standard Institute
Translational Research Office (Medical Sciences Division, University of Oxford)
Organiser contact email address:
Developing a Medical Device: turning your idea into a successful commercial product that’s improving detection, diagnosis or treatment
Members of the University only